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Abstract: BACKGROUND Neurosurgical resection represents an important treatment option in the mod-
ern, multimodal therapy approach of brain metastases (BM). Guidelines for perioperative imaging exist
for primary brain tumors to guide postsurgical treatment. Optimal perioperative imaging of BM patients
is so far a matter of debate as no structured guidelines exist. METHODS A comprehensive question-
naire about perioperative imaging was designed by the European Association of Neuro-Oncology (EANO)
Youngsters Committee. The survey was distributed to physicians via the EANO network to perform a
descriptive overview on the current habits and their variability on perioperative imaging. Chi square test
was used for dichotomous variables. RESULTS One hundred twenty physicians worldwide responded
to the survey. MRI was the preferred preoperative imaging method (93.3%). Overall 106/120 (88.3%)
physicians performed postsurgical imaging routinely including MRI alone (62/120 [51.7%]), postoperative
CT (29/120 [24.2%]) and MRI + CT (15/120 [12.5%]). No correlation of postsurgical MRI utilization in
academic vs. non-academic hospitals (58/89 [65.2%] vs. 19/31 [61.3%], p = 0.698) was found. Early post-
operative MRI within ฀72 h after resection is obtained by 60.8% of the participants. The most frequent
reason for postsurgical imaging was to evaluate the extent of tumor resection (73/120 [60.8%]). In case of
residual tumor, 32/120 (26.7%) participants indicated to adjust radiotherapy, 34/120 (28.3%) to consider
re-surgery to achieve complete resection and 8/120 (6.7%) to evaluate both. CONCLUSIONS MRI was
the preferred imaging method in the preoperative setting. In the postoperative course, imaging modalities
and timing showed high variability. International guidelines for perioperative imaging with special focus
on postoperative MRI to assess residual tumor are warranted to optimize standardized management and
adjuvant treatment decisions for BM patients.
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Abstract
Background: Neurosurgical resection represents an important treatment option in the modern, multimodal therapy
approach of brain metastases (BM). Guidelines for perioperative imaging exist for primary brain tumors to guide
postsurgical treatment. Optimal perioperative imaging of BM patients is so far a matter of debate as no structured
guidelines exist.
Methods: A comprehensive questionnaire about perioperative imaging was designed by the European Association
of Neuro-Oncology (EANO) Youngsters Committee. The survey was distributed to physicians via the EANO network
to perform a descriptive overview on the current habits and their variability on perioperative imaging. Chi square
test was used for dichotomous variables.
Results: One hundred twenty physicians worldwide responded to the survey. MRI was the preferred preoperative
imaging method (93.3%). Overall 106/120 (88.3%) physicians performed postsurgical imaging routinely including
MRI alone (62/120 [51.7%]), postoperative CT (29/120 [24.2%]) and MRI + CT (15/120 [12.5%]). No correlation of
postsurgical MRI utilization in academic vs. non-academic hospitals (58/89 [65.2%] vs. 19/31 [61.3%], p = 0.698) was
found. Early postoperative MRI within ≤72 h after resection is obtained by 60.8% of the participants. The most
frequent reason for postsurgical imaging was to evaluate the extent of tumor resection (73/120 [60.8%]). In case of
residual tumor, 32/120 (26.7%) participants indicated to adjust radiotherapy, 34/120 (28.3%) to consider re-surgery
to achieve complete resection and 8/120 (6.7%) to evaluate both.
Conclusions: MRI was the preferred imaging method in the preoperative setting. In the postoperative course,
imaging modalities and timing showed high variability. International guidelines for perioperative imaging with
special focus on postoperative MRI to assess residual tumor are warranted to optimize standardized management
and adjuvant treatment decisions for BM patients.
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Background
Brain metastases (BM) are a major challenge in modern
oncology, as the limited treatment options result in high
symptomatic burden and poor patient prognosis [1].
Neurosurgical resection represents an important treat-
ment option, especially in patients with solitary BM un-
known histology or risk of hydrocephalus [2].
International guidelines from the European Association
of Neuro-Oncology (EANO) recommend resection of
single, large (diameter ≥ 3 cm) and surgically accessible
BM, and for patients presenting severe neurological
symptoms and good general health [2]. The neurosurgi-
cal goal is to achieve complete resection of BM and sub-
sequent postoperative local radiotherapy/stereotactic
radiosurgery (SRS) is able to minimize local tumor re-
currence risk [2–4]. However, complete neurosurgical
resection might be challenging in some cases as not all
BM present with a clear cut, well-demarcated border to
the surrounding brain parenchyma [5, 6]. BM lacking a
clear-cut demarcation to the surrounding brain paren-
chyma are at particular risk of incomplete resection, po-
tentially contributing significantly to the local recurrence
rate of up to 30.9% after neurosurgical resection [7].
Perioperative imaging is routinely applied to im-
prove neurosurgical resection in glioma patients. Pre-
operative imaging is used to plan and guide surgery
to ensure maximal possible extent of resection and
early (< 72 h after resection) postoperative imaging is
utilized to identify residual tumor [8–11]. Improved
extent of tumor resection has been associated with a
longer progression-free survival and overall survival in
glioma patients, underscoring the need for optimal
tumor resection and the need to address residual
tumor formations [11–15].
Computed tomography (CT) scans were shown to
be insufficient to differentiate between residual tumor
and postoperative bleeding in primary brain tumors,
emphasizing the need for postsurgical magnetic reson-
ance imaging (MRI) to guide further treatment op-
tions [8, 16]. In order to harmonize the perioperative
imaging and optimally guide the therapy approaches,
several international guidelines on glioma treatment
include detailed imaging recommendations [8, 16].
Currently, postoperative MRI within 72 h is routinely
performed at most centers worldwide to investigate
the extent of resection after surgery of diffuse infil-
trating gliomas [17]. Indeed, postoperative MRI fre-
quently impacts adjuvant treatments as re-resection
or adaption of the postoperative treatment can be
considered in case of residual tumor [8, 9, 18].
In contrast, perioperative imaging is not standardized
in BM patients as so far, no guidelines advocate optimal
imaging procedures. Therefore, we aimed to perform a
survey analyzing the routine practice of perioperative
imaging in patients with BM among the EANO network,
to gain insight on the current common practice and es-
pecially the variability throughout centers with academic
and non-academic backgrounds as well as high and low
patient volume centers.
Methods
Study design and targeted population
A survey addressing the perioperative management of
surgically treated BM patients was designed by the
EANO Youngsters committee using an online tool (Sur-
vey Monkey© Inc., San Mateo, California, USA, www.
surveymonkey.com). The EANO Board members
reviewed and approved the survey focus and content.
The survey was sent electronically between May and July
2017 to all members of the EANO, and thereby includ-
ing physicians with a particular focus on neuro-
oncology.
Survey content
This anonymous survey included 19 questions (10 single
and 9 multiple-choice questions) addressing the follow-
ing topics: general information, perioperative standards,
preoperative imaging, intraoperative imaging, applied
imaging techniques including MRI, CT and positron
emission tomography (PET), postoperative imaging and
implementation of a dedicated neuro-oncology tumor
board (see supplemental material for the full survey
questionnaire). Completion of the entire questionnaire
took around 5–10min.
Statistical analysis
The aim of the current study was to provide a descrip-
tive overview on the current habits and their variability
on perioperative imaging within the EANO network. For
statistical purposes countries with 3 or less participants
were combined in the category ‘others’. High volume
centers were defined by a caseload > 50 treated BM pa-
tients per year and low volume centers by a caseload
≤50 BM patients per year. Community hospitals, private
hospitals and private practices were combined in the cat-
egory ‘non-academic center’ while university hospitals
were referred to as ‘academic center’. Chi square test
was used for dichotomous variables. A two-sided p-value
< 0.05 was considered as significant. All analyses were
performed using the software SPSS (IBM SPSS Statistics,
Version 25.0. Armonk, NY: IBM Corp.).
Results
Physicians’ demographical data
The survey was distributed via the EANO newsletter to
1054 E-mailing addresses. A total of 120 questionnaires
from individual physicians were submitted, resulting in a
response rate of 11.4%. The majority of participants were
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neurosurgeons (76/120 [63.3%]), followed by radiation
oncologists (18/120 [15%]), neurologists (17/120
[14.2%]) and medical oncologists (6/120 [5%]; see Table 1
and Fig. 1a for details). Among the participating physi-
cians, 93/120 (77.5%) were from European countries and
27/120 (22.5%) from non-European countries. The ma-
jority of participants (89/120 [74.2%]) were located in
academic centers, while 31/120 (25.8%) were located in
non-academic centers (Fig. 1b). 40/120 (33.3%) physi-
cians worked at high patient volume centers (> 50 BM
patient cases per year) and 71/120 (59.2%) in low patient
volume centers (≤50 BM patient cases per year). Areas
of specialization were evenly distributed within academic
center type (see Fig. 1b and supplementary Table 1 for
details). Further, no difference regarding specialties ac-
cording to patient volume center or center localization
was observed (see Fig. 1c and supplementary Tables 2
and 3 for details). However, participants from academic
centers indicated more frequently to treat a high patient
volume compared to participants from non-academic
centers (39/40 [97.5%] vs. 1/40 [2.5%], p < 0.001).
Preoperative imaging in patients planned for
neurosurgical resection of BM
Preoperative imaging was routinely performed by 114/
120 (95.0%) participating physicians and MRI was the
most commonly applied preoperative imaging technique
(112/120 [93.3%], Table 2 and Fig. 2a and b). The use of
routine preoperative imaging was comparable between
academic and non-academic centers (84/89 [94.4%] vs.
28/31 [90.3%]; p = 0.435, Fig. 2a), low- and high-patient
volume centers (69/71 [97.2%] vs. 40/40 [100%]; p =
0.284, Fig. 2b) and European and non-European coun-
tries (88/93 [94.6%] vs. 24/27 [88.9%]; p = 0.293).
Obtaining preoperative imaging was reported at compar-
able rates for neurosurgeons and participants with other
specialty (73/76 [96.1%] vs. 39/44 [88.6%]; p = 0.117).
Combined preoperative imaging techniques using MRI,
CT and/or PET were applied by 44/120 (36.6%) physi-
cians. The combination of MRI with CT was used more
often compared to MRI and PET combination (27/120
[22.5%] vs. 10/120 [8.3%]) or the triple combination of
MRI, CT and PET (7/120 [5.8%]).
Intraoperative imaging and techniques to guide BM
resection
A total of 59/120 (49.1%) physicians reported that intra-
operative imaging during neurosurgical resection was
conducted at their particular center. The most widely
applied intraoperative imaging technique was intraopera-
tive ultrasound (39/120 [32.5%]) followed by intraopera-
tive MRI or CT (12/120 [10.0%]). Availability rate of
intraoperative MRI or CT was comparable between aca-
demic and non-academic centers (9/12 [75.0%] vs. 3/12
[25.0%]; p = 0.945) or high and low patient volume cen-
ters (7/11 [63.6%] vs. 4/11 [36.4%]; p = 0.981).
Intraoperative neuronavigation was the most fre-
quently applied intraoperative technique for guidance of
BM resection (90/120 [75.0%]), followed by electro-
physiological monitoring/stimulation (56/120 [46.7%]),
and awake surgery (42/120 [35.0%]). 23/120 [19.2%])
physicians indicated to use fluorescence-guided surgery
with 5-aminolevulinic acid (5-ALA). The rate of
fluorescence-guided surgery in non-academic centers
was numerically higher (8/31 [25.8%]) compared to aca-
demic centers (15/89 [16.9%]; p = 0.202; see Table 2).




Radiation Oncology 18 15.0
Neurology 17 14.2
Medical Oncology 6 5.1
(Neuro)Pathology 1 0.8
Radiology 1 0.8













United States of America 4 3.3
Others 40 33.3
Type of institution
Academic/University hospital 89 74.2
Community hospital 15 12.5
Private hospital 14 11.7
Private practice 2 1.6
Number of cases
Low volume center
(≤50 cases per year)
71 59.2
High volume center
(> 50 cases per year)
40 33.3
None 4 3.3
Not known 5 4.2
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Postoperative imaging after neurosurgical BM resection
A total of 106/120 (88.3%) physicians reported to rou-
tinely perform postoperative imaging including MRI
and/or CT within the first days after neurosurgical re-
section. The remaining 6 participants stated to perform
no postoperative imaging (5/120 [4.2%]) or were not
aware of the routine practice at their center (1/120
[0.8%]). 62/120 (51.7%) participants indicated to perform
postoperative MRI alone, 29/120 (24.2%) to perform
postoperative CT and the residual 15/120 (12.5%) partic-
ipants stated to prefer the combination of MRI and CT
imaging (Fig. 3a and Table 3). Postoperative CT was per-
formed to excluded postoperative complications such as
hematoma or ischemia according to 29/120 (24.2%) par-
ticipants. 10/120 (8.3%) physicians indicated to perform
a CT in the postoperative course to evaluate the extent
of tumor resection. Medical oncologists (3/6 [50%]) re-
ported the need for a postoperative MRI less frequently
compared to neurologists (12/17 [70.6%]), radiation on-
cologists (14/18 [77.8%]) and neurosurgeons (47/76
[61.8%], p = 0.484; Fig. 3a and b). Indication for postop-
erative MRI was given at comparable rates between par-
ticipants from academic and non-academic centers (58/
89 [65.2%] vs. 19/31 [61.3%], p = 0.698; Fig. 3c) as well
as from high and low patient volume centers (49/71
[69.0%] vs 25/40 [62.5%], p = 0.485; Fig. 3d). Participants
from European countries indicated the use of postopera-
tive MRI more frequently compared to participants from
non-European countries (64/93 [68.8%] vs. 13/27
[48.1%], p = 0.049).
Early postoperative MRI within ≤72 h after resection
was indicated to be routinely performed by 73/120
(60.8%) physicians. The number of BM (26/120 [21.7%]),
histology of primary tumor (18/120 [15%]), previous
therapies (18/120 [15%]) and the graded prognostic as-
sessment class/life expectancy of patient (12/120 ([10%])
were nominated parameters influencing the time point
of postoperative MRI. Evaluating the extent of resection
was the most commonly reported reason to perform a
postoperative MRI (73/120 [60.8%]). In case of residual
tumor in the postoperative MRI, 32/120 (26.7%) partici-
pants indicated to adjust the radiotherapy plan, 34/120
(28.3%) to consider re-resection in order to achieve
complete and 8/120 (6.7%) stated to consider both.
No availability of postoperative MRI (13/120 [10.8%])
or high costs (9/120 [7.5%]) were the most frequent rea-
sons to omit postoperative MRI.
Standard operating procedures for perioperative imaging
Local standard operating procedures (SOP) on the peri-
operative imaging in BM patients were available for 94/
120 (78.3%) physicians (Table 2). No difference in the
use of local SOP for perioperative imaging between par-
ticipants from academic and non-academic centers (68/
89 [76.4%] vs. 26/31 [83.9%]; p = 0.385), high and low
patient volume centers (56/71 [78.9%] vs. 35/40 [87.5%];
p = 0.256) or European and non-European countries
(73/93 [78.5%] vs. 21/27 [77.8%]; p = 0.937) was evident.
Availability of a dedicated neuro-oncology tumor board
for BM patients
Treatment plans for BM patients were discussed in a
dedicated neuro-oncology tumor board by 98/120
(81.7%) participating physicians. Dedicated neuro-
oncology tumor boards were established at comparable
rates in academic and non-academic centers (73/89
[82.0%] vs. 25/31 [80.6%]; p = 0.864), in high and low pa-
tient volume centers (62/71 [87.3%] vs. 34/40 [85%]; p =
0.731) and in European vs. non-European countries (77/
93 [82.8%] vs. 21/27 [77.8%]; p = 0.553). Both pre- as
well as additional postoperative discussion of the indi-
vidual cases were performed by 63/98 (64.2%)
physicians.
Discussion
Neurosurgical resection is an important treatment op-
tion in the multimodal management of BM patients [2].
Although BM represent the most common brain tumors,
Fig. 1 a The distribution of the participants throughout the specialties showed the highest participation of neurosurgeons followed by radiation
oncologists and neurologists with a similar distribution in b academic versus non-academic centers and c high versus low volume centers
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perioperative imaging guidelines for surgically treated
BM to standardize optimal adjuvant treatment are so far
lacking. The present survey conducted by the EANO
Youngsters Committee is the first to evaluate the current
perioperative imaging modalities in BM patients. A total
of 120 physicians worldwide, from academic as well as
non-academic centers, high and low volume centers,
European and non-European countries, participated in
this survey. The survey revealed that MRI is the
preferred perioperative imaging technique and is rou-
tinely applied in the preoperative setting, whereas a high
variability of postoperative neuroimaging routines (in-
cluding CT and MRI) was observed throughout the
EANO network.
MRI was the most commonly applied preoperative im-
aging technique, regardless of the investigated center
and geographical localization. Preoperative MRI is a
broadly established diagnostic tool to plan treatment op-
tions of BM including surgery, radiation therapy, radio-
surgery and systemic treatments [2, 16, 19–23].
Differentiation of BM from other tumor entities, such as
malignant gliomas or lymphomas, as well as pseudopro-
gression/radionecrosis, is predominately based on pre-
operative MRI [16, 20, 21, 23]. Aside from diagnostic
evaluation of presurgical MRI, this important tool also
supports the neurosurgeon’s approach to surgical plan-
ning [24–26]. Based on the experiences and recommen-
dations for primary brain tumors, additional diffusion
tensor imaging (DTI) can be applied in case of eloquent
localizations also in BM patients in order to improve
preoperative definition of the surgical strategy as well as
subsequent intraoperative navigation to avoid injury of
functional white matter tracts [26, 27]. Nevertheless, the
so far existing preoperative imaging recommendations
from primary brain tumors would need validation in BM
patients [28].
Neuronavigation was the most frequently applied in-
traoperative technique during BM resection, as it repre-
sents currently the standard for preoperative planning
and intraoperative guidance [29–31]. Furthermore, elec-
trophysiological monitoring/stimulation and awake sur-
gery were used by some of the participating physicians.
These techniques are useful to minimize the risk of a
new postoperative neurological deficit and thus support
the neurosurgeon to achieve safe resection of BM also in
eloquent tumor localizations [32–34]. Moreover, one
fourth of physicians reported to use fluorescence-guided
surgery with 5-aminolevulinic-acid (5-ALA). To date,
fluorescence-guided surgery is mainly used for resection
of high-grade gliomas, but recently was also described to
be useful for intraoperative visualization of BM tissue [7,
35–37]. Intraoperative MRI or CT were infrequently ap-
plied, potentially as a consequence of the high costs and
the low acceptance in BM surgery. However, due to the
frequent lack of clear delineation of BM towards the sur-
rounding brain parenchyma intraoperative techniques
and especially 5-ALA might be of additional value to en-
sure optimal extent of resection [6].
The majority of physicians performed a postsurgical
MRI, although only approximately half of the participat-
ing physicians indicated to perform early postoperative
MRI within 72 h after tumor resection. No differences in
the use of postsurgical MRI were evident between
Table 2 Pre- and intraoperative imaging of patients treated
with resection of BM
n %
Standards for perioperative imaging
Yes 94 78.3
No 14 11.7
Not known 12 10.0
Imaging is supervised by …
Neuroradiologist 98 81.7
General radiologist 12 10.0
Neurosurgeon 1 0.8
Not known 9 7.5





MRI alone 68 56.7
MRI + CT 27 22.5
MRI + PET 10 8.3
MRI + CT + PET 7 5.8
CT alone 2 1.7
Not known 6 5.0
Preoperative MRI protocol
Standard MRI protocol 68 56.7
Advanced imaging protocol 40 33.3
Shortened MRI protocol 2 1.7
Not known 10 8.3
Intraoperative techniques
Neuronavigation 90 75.0
Electrophysiological monitoring/stimulation 56 46.7
Awake surgery 42 35.0
Intraoperative ultrasound 39 32.5
Fluorescence-guided surgery 23 19.2
Intraoperative MRI 9 7.5
Intraoperative CT 3 2.5
Not known 11 9.2
CT computed tomography, MRI magnetic resonance imaging, PET positron
emission tomography
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academic and non-academic centers, while European
participants reported the use more frequently than non-
European participants. Interestingly, differences were ob-
served according to the medical specialties. Oncologists
reported less frequent use of post-surgical imaging com-
pared to the other specialties. EANO guidelines on diag-
nosis and treatment of BM recommend postoperative
MRI to guide adjuvant radiotherapy applied to the
resection cavity as the postsurgical resection cavity vol-
ume is smaller than preoperative BM volume [2]. How-
ever, no recommendation on the optimal timepoint for
postoperative MRI after BM resection is given in the
current version. As indeed timing is stated to be not
relevant for this particular postoperative application [2].
Importantly, postsurgical changes, such as ischemia,
bleeding, or postsurgical gliosis frequently occur and
Fig. 2 Application of preoperative imaging methods revealed MRI as the most frequently applied preoperative method throughout (a) academic
versus non-academic and (b) low versus high volume centers
Fig. 3 a, b The application of postoperative MRI was more important for neurosurgeons followed by radiation oncologist and neurologists
compared to medical oncologists. c Academic versus non-academic as well as d low and high volume centers equally performed MRI in the
postoperative setting
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may mimic a residual tumor in case of MRI is performed
later than 72 h after resection [8]. In glioma surgery, sev-
eral guidelines stress the importance of an early postop-
erative MRI within 72 h after surgery to reliably
differentiate postsurgical changes and residual tumor
and guide the subsequent therapeutic approach [8]. A
recent publication revealed residual tumor on early post-
operative MRI in 20% of BM cases, although 92.3% of
these were classified as complete resection by the sur-
geon [38]. These observations further stress the import-
ance of accurately accessing the tumor residue with
early postsurgical MRI and including this information in
the further treatment plan.
More than half of the participants indicated to adjust
the radiotherapy plan or even consider re-do surgery to
achieve complete resection in case of residual tumor in
the early postoperative MRI. Indeed, adjuvant therapy
after BM resection has been controversially discussed.
Whole brain radiotherapy (WBRT) has been shown to
increase local tumor control as well as the distant brain
control [4, 39, 40]. However, WBRT had no impact on
overall survival [4, 39, 40]. Due to potential neuro-
Table 3 Postoperative imaging of patients treated with resection of BM
n %
Postoperative imaging
Postoperative MRI 77 64.2
Postoperative CT 44 36.7
No postoperative imaging 5 4.2
Not known 1 0.8
Time point of postoperative MRI
≤ 72 h after resection 73 60.8
> 72 h to 7 days after resection 2 1.7
> 7 days to 4 weeks after resection 7 5.8
> 4 weeks to 3 months after resection 18 15.0
> 3months after resection 4 3.3
Very variable 1 0.8
Not known 15 12.6
Reasons for postoperative MRI
To evaluate the extent of resection 73 60.8
To exclude postoperative complications (hematoma, ischemia ...) 34 28.3
For research purpose 8 6.7
Parameters influencing time point of postoperative MRI
Number of BM 26 21.7
Histology of primary tumor 18 15.0
Previous therapy of BM 18 15.0
GPA class/life expectancy of patient 12 10.0
None 58 48.3
Not known 4 3.3
Consequences in case of residual tumor
Adjustment of the radiotherapy plan 32 26.7
Considering re-do surgery to achieve complete resection 34 28.3
both 8 6.7
Causes of lack of postoperative MRI
Considered unnecessary 17 14.2
No capacity/availability 13 10.8
Due to high costs 9 7.5
Intraoperative MRI already performed 0 0
BM brain metastases, CT computed tomography, MRI magnetic resonance imaging
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cognitive decline, WBRT is currently controversial in
EANO guidelines [41, 42]. Adjuvant Stereotactic frac-
tionated radiotherapy (SFRT) or stereotactic radiosur-
gery (SRS) of the resection cavity has been suggested to
increase the local disease control [33, 43]. So far only
very small studies address the clinical impact of early
postsurgical imaging in BM [38, 44]. One recent publica-
tion stressed that routine postoperative MRI is unneces-
sary because patients with small residual tumor did not
undergo any changes of treatment plan [44]. In this
retrospective study, the authors recommended postoper-
ative imaging only in case of neurological deficits, con-
cerns about large amounts of residual tumor or
intraoperative complications [44]. However, considering
the new opportunities of adjuvant SRS/SFRT, this might
not hold true in modern BM management and should
be investigated in further clinical trials.
The majority of participants of our survey stated to
conduct perioperative imaging in BM according to local
SOP. These findings were independent of academic vs.
non-academic centers or European vs. non-European
countries. Guidelines on the perioperative imaging are
well established in primary brain tumors, but are missing
so far for BM [8]. Especially in high-grade glioma pa-
tients, the evaluation of the extent of resection plays an
important role for prognosis [13, 45]. Several studies in-
dicated a better progression-free and overall survival in
case of complete resection of the contrast enhancing
tumor [13, 45].
Based on the results of our survey, international guide-
lines for perioperative imaging in BM are warranted to
ensure a standardized optimal postoperative treatment
approach and to provide a comparable standard through
centers. In our view, the most appropriate method of
perioperative imaging in BM represents MRI. In this
sense, we recommend performing a standardized pre-
operative MRI protocol for optimal tumor diagnosis, se-
lection of the appropriate treatment option and
preoperative planning. After surgery of BM, we suggest
conducting a standardized early postsurgical MRI within
72 h after surgery to evaluate especially the extent of
tumor resection and thus optimize subsequent treatment
allocation. In case of a significant postsurgical residual
tumor, we propose to consider a re-do surgery or adjust-
ment of the radiotherapy plan.
Our survey was performed anonymously to reduce a
potential bias based on reporting the treatment institu-
tion. However, in consequence we did not include the
identification of the center and therefore cannot address
how many participants from the same center answered
the survey. Certainly, physicians with a particular focus
on BM treatment were more likely to answer the survey
out of interest and therefore bias the given results.
Nevertheless, we provide the first investigation of the
current practice of perioperative imaging in BM patients,
showing a particular variability in the postoperative im-
aging modalities and therefore stressing the need for
international guidelines to harmonize optimized peri-
operative treatment algorithms.
Conclusion
In conclusion, we were able to conduct the first inter-
national survey on perioperative imaging in BM patients.
Although the majority of included physicians routinely
use perioperative MRI, only half obtain early postopera-
tive MRI to reliably identify residual tumor. No availabil-
ity of postoperative MRI or high costs were the most
frequent reasons to omit postoperative MRI. Inter-
national guidelines on the perioperative imaging may
help to optimize treatment approaches and ensure a
high level of standard treatment throughout centers.
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